<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2373">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04551898</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-DXP593-102</org_study_id>
    <nct_id>NCT04551898</nct_id>
  </id_info>
  <brief_title>Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody BGB-DXP593 in Patients WithMild-to-Moderate COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to investigate the safety and tolerability of&#xD;
      BGB-DXP593 administered intravenously as a single dose in participants with mild-to-moderate&#xD;
      COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2, 2020</start_date>
  <completion_date type="Actual">January 25, 2021</completion_date>
  <primary_completion_date type="Actual">January 25, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to Day 8 in SARS-CoV-2 viral shedding as measured by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal swab samples</measure>
    <time_frame>Up to 8 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time-weighted average change in viral shedding as measured by RT-qPCR in nasopharyngeal swab samples</measure>
    <time_frame>Baseline to Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Day 15 in SARS-CoV-2 viral shedding as measured by RT-qPCR in nasopharyngeal swab samples</measure>
    <time_frame>Baseline to Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to negative RT-qPCR in all tested samples with no subsequent positive RT-qPCR in any tested samples</measure>
    <time_frame>Up to 15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants requiring hospitalization due to worsened COVID-19</measure>
    <time_frame>Up to 29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to resolution of all COVID-19-related symptoms</measure>
    <time_frame>Up to 29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality rate at Day 29</measure>
    <time_frame>Up to 29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing Adverse Events (AEs)</measure>
    <time_frame>Up to 85 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 85 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">181</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>BGB-DXP593 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive BGB-DXP593 on Day 1, and followed up for safety for up to 85 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BGB-DXP593 Medium Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive BGB-DXP593 on Day 1, and followed up for safety for up to 85 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BGB-DXP593 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive BGB-DXP593 on Day 1, and followed up for safety for up to 85 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo on Day 1, and followed up for safety for up to 85 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGB-DXP593</intervention_name>
    <description>Intravenous (IV) infusion administered over 30 to 60 minutes at a dose as specified in the treatment arm</description>
    <arm_group_label>BGB-DXP593 High Dose</arm_group_label>
    <arm_group_label>BGB-DXP593 Low Dose</arm_group_label>
    <arm_group_label>BGB-DXP593 Medium Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match BGB-DXP593 administered as specified in the treatment arm</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Laboratory-confirmed severe acute respiratory syndrome (SARS)-CoV-2 infection&#xD;
             (positive reverse transcription-polymerase chain reaction [RT-PCR] test or other&#xD;
             authorized antigen testing methods) in any samples following local practice ≤ 72 hours&#xD;
             prior to screening.&#xD;
&#xD;
          2. Have experienced COVID-19 symptoms for ≤ 7 days prior to treatment assignment, such as&#xD;
             fever, cough, shortness of breath, sore throat, diarrhea, vomiting, and dysgeusia&#xD;
&#xD;
          3. Agree to the collection of nasopharyngeal swabs, saliva, and venous blood&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Severe COVID-19 having oxygen saturation (SpO2) ≤ 93 % on room air at sea level or&#xD;
             ratio of arterial oxygen partial pressure (PaO2 in millimeters of mercury) to&#xD;
             fractional inspired oxygen (FiO2) &lt; 300, respiratory rate ≥ 30/min, heart rate ≥&#xD;
             125/min&#xD;
&#xD;
          2. Requires mechanical ventilation or anticipated impending need for mechanical&#xD;
             ventilation&#xD;
&#xD;
          3. Known allergies to any of the components used in the formulation of the interventions&#xD;
&#xD;
          4. Have received an investigational intervention for SARS-CoV-2 prophylaxis within 30&#xD;
             days before dosing&#xD;
&#xD;
          5. Have received treatment with a SARS-CoV-2 specific monoclonal antibody&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhen Yao, MD</last_name>
    <role>Study Director</role>
    <affiliation>BeiGene</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Elixia</name>
      <address>
        <city>Hollywood</city>
        <state>California</state>
        <zip>33023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midland Florida Clinical Research Center, LLC</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Medical Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>33207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Homestead Associates in Research Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research Center of Miami II, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US Associates in Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Continental Research Network</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33187</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Research Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revival Research Institute, LLC.</name>
      <address>
        <city>Dearborn</city>
        <state>Michigan</state>
        <zip>48126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Phase Research &amp; Development</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amarillo Center for Clinical Research</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PanAmerican Clinical Research</name>
      <address>
        <city>Brownsville</city>
        <state>Texas</state>
        <zip>78520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundação Universidade de Caxias do Sul - Instituto de Pesquisas em Saúde</name>
      <address>
        <city>Petropolis</city>
        <state>Caxias Do Sul</state>
        <zip>95070</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clínicas da Faculdade de Medicina de Botucatu</name>
      <address>
        <city>Botucatu</city>
        <zip>18618</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irmandade da Santa Casa de Misericórdia de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90020</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitáro de Santa Maria / UFSM</name>
      <address>
        <city>Santa Maria</city>
        <zip>97105</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMPC Pesquisa Clinica</name>
      <address>
        <city>Sorocaba</city>
        <zip>18040</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Cardiologica Aguascalientes</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20230</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JM Research</name>
      <address>
        <city>Cuernavaca</city>
        <zip>62290</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Dr. Manuel Gea Gonzalez</name>
      <address>
        <city>Mexico</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iecsi S.C.</name>
      <address>
        <city>Monterrey</city>
        <zip>58249</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica de Enfermedades Cronicas y de Procedimientos Especiales, S.C.</name>
      <address>
        <city>Morelia</city>
        <zip>58249</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kohler &amp; Milstein Research</name>
      <address>
        <city>Mérida</city>
        <zip>97070</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PanAmerican Clinical Research</name>
      <address>
        <city>Querétaro</city>
        <zip>76226</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Rand Research T/A Worthwhile Clinical Trials</name>
      <address>
        <city>Benoni</city>
        <zip>1501</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TASK</name>
      <address>
        <city>Cape Town</city>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TREAD Research CC</name>
      <address>
        <city>Cape Town</city>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Langeberg Clinical Trials</name>
      <address>
        <city>Cape Town</city>
        <zip>7570</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wits Clinical Research</name>
      <address>
        <city>Soweto</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Mexico</country>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 10, 2020</study_first_submitted>
  <study_first_submitted_qc>September 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

